ATAI Life Sciences N.V.: M&A transaction — ATAI acquires additional ~11.2M shares in Beckley Psytech for $10M, raising stake to 35.47%

ATAI Life Sciences N.V.

Secondary purchase of 11,153,246 shares from existing shareholders at ~$0.8966/share, total $10M.
Combined with Jan 3 primary investment of $40M for 24.1M Series C shares, total outlay ~$50M.
ATAI now holds a 35.47% voting interest in Beckley Psytech Limited.
All acquired shares re-designated as Series C preferred shares; investment closed on Jan 18, 2024.
Transaction structured via Share Purchase Deed; warrants customary representations from sellers.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.95

ATAI Life Sciences N.V. completed an acquisition involving Beckley Psytech Limited for total purchase price of US $10,000,000.37 (closed 2024-01-18).

Action: acquisition
Counterparty: Beckley Psytech Limited
Consideration: total purchase price of US $10,000,000.37
Closing: 2024-01-18

Exact text from the filing

On January 18, 2024, pursuant to the SSA, the Company entered into a Share Purchase Deed (the “Secondary Sale SPA”), pursuant to which the Company acquired a total of 11,153,246 additional shares of BPL from certain existing shareholders of BPL, for a total purchase price of US $10,000,000.37

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ATAI Life Sciences N.V. entered into subscription and shareholders’ agreement with Beckley Psytech Limited and certain other shareholders valued at $39,999,999.10 (effective 2024-01-03).

Action: entry
Agreement: equity purchase
Counterparty: Beckley Psytech Limited and certain other shareholders
Value: $39,999,999.10
Effective: 2024-01-03

Exact text from the filing

on January 3, 2024, atai Life Sciences N.V. (the “Company”) entered into that certain subscription and shareholders’ agreement with Beckley Psytech Limited, a company incorporated in England and Wales (“BPL”), and certain other shareholders of BPL, as identified in such agreement (the “SSA”), under which, among other things, the Company acquired 24,096,385 newly issued series C preferred shares, par value £0.0001 per share, of BPL (the “Series C Shares”) for a total purchase price of $39,999,999.10

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ATAI Life Sciences N.V. entered into Share Purchase Deed with certain existing shareholders of BPL valued at $10,000,000.37 (effective 2024-01-18).

Action: entry
Agreement: equity purchase
Counterparty: certain existing shareholders of BPL
Value: $10,000,000.37
Effective: 2024-01-18

Exact text from the filing

On January 18, 2024, pursuant to the SSA, the Company entered into a Share Purchase Deed (the “Secondary Sale SPA”), pursuant to which the Company acquired a total of 11,153,246 additional shares of BPL from certain existing shareholders of BPL, for a total purchase price of US $10,000,000.37

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001140361-24-003285

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.